Blood Group Genotyping for Sickle Cell and Thalassaemia
Details
| Contract Title: | Blood Group Genotyping for Sickle Cell and Thalassaemia |
| Published Date: | Jun 11, 2026 |
| Notice Type: | Award (ContractAwardNotice) |
| Value Banding: | High Value |
| Delivery Point: | United Kingdom |
Description:
Embedding blood group genotyping into routine practice. The primary objective (benefit) of doing so is to ensure patients with rare blood disorders have a minimise risk of adverse reactions through access to blood group genotyping. Due to delays arising from administrative and operational circumstances, NHS England awarded this contract to commencing 25 June 2025 until 31 March 2026....